Home › Compare › AVHNY vs ABBV
AVHNY yields 0.88% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, AVHNY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AVHNY + ABBV for your $10,000?
Ackermans & Van Haaren NV engages in the marine engineering and contracting, private banking, real estate and senior care, and energy and resources businesses worldwide. The company operates through five segments: Marine Engineering & Contracting, Private Banking, Real Estate & Senior Care, Energy & Resources, and AvH & Growth Capital. It engages in the marine construction activities, including dredging and civil works on water, as well as offshore activities in the areas of renewable energy, oil and gas, soil and sludge remediation, and aggregate and mineral extraction; real estate development activities; and development of port projects and related industrial zones, as well as offshore wind farms. The company also offers asset management services for various private clients; advisory banking services for entrepreneurs and liberal professionals; and car finance and leasing services through car dealers. In addition, it develops residential and mixed projects; invests in retail and office properties; provides accommodation and care for the elderly; and operates retirement homes. Further, the company produces crude palm oil, rubber, banana, and tea products; manufactures cement; and offers advice, automation, and maintenance services for life science, tank terminal, food and beverage, infrastructure, and chemistry markets. Additionally, it engages in the production and sale of compact biogas installations. Ackermans & Van Haaren NV was founded in 1876 and is headquartered in Antwerp, Belgium.
Full AVHNY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.